Neurochase
Medical Equipment Manufacturing • 
London, England, United Kingdom • 1-10 Employees
Company overview
| Headquarters | 2 Swan Lane, London, England EC4R 3, GB |
| Phone number | +447507158943 |
| Website | |
| NAICS | 3391 |
| Keywords | Neuroscience, Medical Devices, Neurosurgery, Longevity |
| Founded | 2020 |
| Employees | 1-10 |
| Socials |
Key Contacts at Neurochase
Sharon Kane
Chief Executive Officer
Keith Murdoch
Financial Director
Steven Gill
Founder & Cso Neurochase
Neurochase Email Formats
Neurochase uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@neurochase.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@neurochase.com | 66.7% |
{first name}.{last name} | john.doe@neurochase.com | 33.3% |
About Neurochase
About Us: Neurochase was founded by a team of physician-scientists led by Professor Steven Gill in response to the growing need for CED consultancy services in the life science industry. Professor Gill is an Honorary Professor of Neurosurgery at the University of Bristol. He is a world leading expert in CED and has spent the past 20 years developing technology to facilitate highly accurate and safe targeting of deep brain structures using software and surgical robots. To learn more about Professor Gill, watch the following video interview where he discusses his clinical experience of intermittently delivering chemotherapy directly to paediatric brainstem tumours using his novel implantable neurosurgical device. Our Science: Convection Enhanced Delivery (CED) provides a method of achieving effective doses of therapeutics homogenously in targeted brain volumes that cannot be achieved safely with systemic or CSF delivery. Therapies are infused into the brain via micro-catheters and can be distributed in tightly controlled doses throughout the required treatment volume. The blood brain barrier now acts to retain the therapy in the brain targets thereby minimising systemic and off-target exposure. We believe that safe and scalable delivery of novel therapeutics by CED is achievable and will transform human health by unlocking treatments to previously untreatable neurological disorders.
Neurochase revenue & valuation
| Annual revenue | $769,995 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Medical Equipment Manufacturing industry and current estimated revenues | $2,500,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Neurochase has 5 employees across 4 departments.
Departments
Number of employees
Funding Data
Neurochase has never raised funding before.
Neurochase Tech Stack
Discover the technologies and tools that power Neurochase's digital infrastructure, from frameworks to analytics platforms.
Web servers
Font scripts
Programming languages
Miscellaneous
SEO
JavaScript frameworks
Blogs
JavaScript libraries
Video players
Page builders
Databases
CDN
Italy
United States
NetherlandsFrequently asked questions
4.8
40,000 users
